Está indicado para el tratamiento de adultos con: leucemia mieloide crónica (lmc) con cromosoma Philadelphia positivo (ph+) en fase crónica de diagnóstico reciente. Lmc ph+ en fase crónica, acelerada, o mieloblastica o linfoblastica con resistencia o intolerancia a tratamiento previo, incluido imatinib. Leucemia linfoblastica aguda con cromosoma Philadelfia positivo (lla ph+) con resistencia o intolerancia a tratamiento previo.
- NCCN Guidelines Version 2.2017 Updates Chronic Myeloid Leukemia
- Alikian M, Gale RP, Apperley JF, Foroni L. Molecular techniques for the personalised management of patients with chronic myeloid leukaemia. Biomol Detect Quantif 2017; 11: 4-20.
- Wei et al.: First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. Journal of Hematology & Oncology 2010 3:47.
- Agrawal M, Garg RJ, Cortes J, Quintas-Cardama A: Tyrosine kinase inhibitors: the first decade. Curr Hematol Malig Rep 2010, 5:70-80.
- Huang R, Kang Q, Liu H, Li Y. New insights into the molecular resistance mechanisms of chronic myeloid leukemia. Curr Cancer Drug Targets 2016; 16: 323-45.
- Tortorella SM, Hung A, Karagiannis TC. The implications of cancer progenitor cells and the role of epigenetics in the development of novel therapeutic strategies for chronic myeloid leukemia. Antioxid Redux Signal 2015; 22: 1425-62.